BR112020023559A2 - método para preparar um enantiômero de tipifarnib desejado e método para transformar uma amina enantiomericamente enriquecida - Google Patents
método para preparar um enantiômero de tipifarnib desejado e método para transformar uma amina enantiomericamente enriquecida Download PDFInfo
- Publication number
- BR112020023559A2 BR112020023559A2 BR112020023559-8A BR112020023559A BR112020023559A2 BR 112020023559 A2 BR112020023559 A2 BR 112020023559A2 BR 112020023559 A BR112020023559 A BR 112020023559A BR 112020023559 A2 BR112020023559 A2 BR 112020023559A2
- Authority
- BR
- Brazil
- Prior art keywords
- fact
- mixture
- tipifarnib
- racemic
- enantiomer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 131
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical class CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 title claims abstract description 89
- 150000001412 amines Chemical class 0.000 title claims description 20
- 230000001131 transforming effect Effects 0.000 title claims description 13
- 229950009158 tipifarnib Drugs 0.000 claims abstract description 71
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 142
- 239000000203 mixture Substances 0.000 claims description 130
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 123
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 76
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 75
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 68
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 66
- 239000002904 solvent Substances 0.000 claims description 66
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 58
- 239000012452 mother liquor Substances 0.000 claims description 44
- 239000003960 organic solvent Substances 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 34
- 230000008569 process Effects 0.000 claims description 34
- 239000007858 starting material Substances 0.000 claims description 34
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 32
- 235000010288 sodium nitrite Nutrition 0.000 claims description 30
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 229940011051 isopropyl acetate Drugs 0.000 claims description 20
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical group CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 20
- 239000007810 chemical reaction solvent Substances 0.000 claims description 19
- 239000000654 additive Substances 0.000 claims description 17
- 230000000996 additive effect Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000002425 crystallisation Methods 0.000 claims description 14
- 230000008025 crystallization Effects 0.000 claims description 14
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 9
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 7
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 6
- 239000000908 ammonium hydroxide Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 3
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- PLHJCIYEEKOWNM-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-UHFFFAOYSA-N 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 11
- 238000006243 chemical reaction Methods 0.000 description 94
- 238000002474 experimental method Methods 0.000 description 92
- 239000000047 product Substances 0.000 description 51
- 238000003756 stirring Methods 0.000 description 50
- 239000007787 solid Substances 0.000 description 48
- 239000011541 reaction mixture Substances 0.000 description 44
- 239000000243 solution Substances 0.000 description 42
- MVODTGURFNTEKX-UHFFFAOYSA-N 2-bromo-n-(2-bromoethyl)-n-(thiophen-2-ylmethyl)ethanamine;hydrobromide Chemical compound Br.BrCCN(CCBr)CC1=CC=CS1 MVODTGURFNTEKX-UHFFFAOYSA-N 0.000 description 34
- 238000011835 investigation Methods 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 239000010410 layer Substances 0.000 description 15
- 238000011084 recovery Methods 0.000 description 14
- 238000012369 In process control Methods 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 239000012535 impurity Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 230000006340 racemization Effects 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 235000011149 sulphuric acid Nutrition 0.000 description 8
- 239000012071 phase Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- -1 1-methyl-1H-imidazol-5-yl Chemical group 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000010354 integration Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000002879 Lewis base Substances 0.000 description 4
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 4
- 150000007527 lewis bases Chemical class 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000007848 Bronsted acid Substances 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000006104 solid solution Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 2
- IDKYCLCDTGIFBA-UHFFFAOYSA-N 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound C=1C(=O)N(C)C2=CC=C(C(=O)C=3C=CC(Cl)=CC=3)C=C2C=1C1=CC=CC(Cl)=C1 IDKYCLCDTGIFBA-UHFFFAOYSA-N 0.000 description 2
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 2
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- YONLFQNRGZXBBF-UHFFFAOYSA-N 2,3-dibenzoyloxybutanedioic acid Chemical class C=1C=CC=CC=1C(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- WOYOASASOHZEDR-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(O)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 WOYOASASOHZEDR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101710091417 DNA-binding protein TubR Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005112 continuous flow technique Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- IWYZTXQESXGICT-UHFFFAOYSA-N dibenzoyl butanediperoxoate Chemical compound C(CCC(=O)OOC(C1=CC=CC=C1)=O)(=O)OOC(C1=CC=CC=C1)=O IWYZTXQESXGICT-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 108091005640 farnesylated proteins Proteins 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000012663 orally bioavailable inhibitor Substances 0.000 description 1
- 229940044205 orally bioavailable inhibitor Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B55/00—Racemisation; Complete or partial inversion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673693P | 2018-05-18 | 2018-05-18 | |
| US62/673,693 | 2018-05-18 | ||
| PCT/US2019/032765 WO2019222565A1 (en) | 2018-05-18 | 2019-05-17 | Synthesis of tipifarnib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020023559A2 true BR112020023559A2 (pt) | 2021-02-09 |
Family
ID=66770583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020023559-8A BR112020023559A2 (pt) | 2018-05-18 | 2019-05-17 | método para preparar um enantiômero de tipifarnib desejado e método para transformar uma amina enantiomericamente enriquecida |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11542244B2 (https=) |
| EP (1) | EP3793966A1 (https=) |
| JP (1) | JP2021526513A (https=) |
| KR (1) | KR20210039987A (https=) |
| CN (1) | CN112424149B (https=) |
| AU (1) | AU2019270163A1 (https=) |
| BR (1) | BR112020023559A2 (https=) |
| CA (1) | CA3100706A1 (https=) |
| EA (1) | EA202092787A1 (https=) |
| MX (1) | MX2020012305A (https=) |
| PH (1) | PH12020551956A1 (https=) |
| SG (1) | SG11202011378WA (https=) |
| WO (1) | WO2019222565A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102839264B1 (ko) | 2023-03-07 | 2025-07-29 | 단국대학교 천안캠퍼스 산학협력단 | 티피파르닙을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE214695T1 (de) | 1994-09-23 | 2002-04-15 | Darwin Discovery Ltd | Racemisierungsverfahren bei der herstellung von levobupivacaine und analogen |
| AU702594B2 (en) * | 1995-10-13 | 1999-02-25 | Duphar International Research B.V. | Process for the preparation of enantiomerically pure imidazolyl compounds |
| DE69620445T2 (de) | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica N.V., Beerse | (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren |
| BRPI0208075B8 (pt) * | 2001-03-12 | 2021-05-25 | Janssen Pharmaceutica Nv | processo para a preparação de compostos de imidazol |
| DE602005007604D1 (de) * | 2004-05-03 | 2008-07-31 | Janssen Pharmaceutica Nv | Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine |
| JP5008554B2 (ja) * | 2004-05-03 | 2012-08-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | イミダゾール化合物の製造用のジアステレオ選択的合成方法 |
| CN100567291C (zh) * | 2004-05-03 | 2009-12-09 | 詹森药业有限公司 | 用6-溴-4-(3-氯苯基)-2-甲氧基喹啉进行的非对映选择性合成方法 |
| EP3221311B1 (en) * | 2014-11-21 | 2019-10-30 | Merck Patent GmbH | Method for the production of praziquantel |
| CN104876856B (zh) | 2015-05-05 | 2017-11-21 | 河北凯力昂生物科技有限公司 | 一种拆分法制备(r)‑(+)‑3‑氨基哌啶二盐酸盐的方法 |
-
2019
- 2019-05-17 CA CA3100706A patent/CA3100706A1/en active Pending
- 2019-05-17 EA EA202092787A patent/EA202092787A1/ru unknown
- 2019-05-17 KR KR1020207036324A patent/KR20210039987A/ko not_active Withdrawn
- 2019-05-17 CN CN201980047803.3A patent/CN112424149B/zh active Active
- 2019-05-17 AU AU2019270163A patent/AU2019270163A1/en not_active Abandoned
- 2019-05-17 JP JP2020564572A patent/JP2021526513A/ja not_active Withdrawn
- 2019-05-17 EP EP19728818.6A patent/EP3793966A1/en not_active Withdrawn
- 2019-05-17 WO PCT/US2019/032765 patent/WO2019222565A1/en not_active Ceased
- 2019-05-17 MX MX2020012305A patent/MX2020012305A/es unknown
- 2019-05-17 US US17/056,745 patent/US11542244B2/en active Active
- 2019-05-17 SG SG11202011378WA patent/SG11202011378WA/en unknown
- 2019-05-17 BR BR112020023559-8A patent/BR112020023559A2/pt not_active Application Discontinuation
-
2020
- 2020-11-16 PH PH12020551956A patent/PH12020551956A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021526513A (ja) | 2021-10-07 |
| PH12020551956A1 (en) | 2021-08-16 |
| CA3100706A1 (en) | 2019-11-21 |
| US20210246114A1 (en) | 2021-08-12 |
| EA202092787A1 (ru) | 2021-02-09 |
| MX2020012305A (es) | 2021-03-25 |
| KR20210039987A (ko) | 2021-04-12 |
| AU2019270163A1 (en) | 2020-12-03 |
| CN112424149A (zh) | 2021-02-26 |
| CN112424149B (zh) | 2023-06-23 |
| EP3793966A1 (en) | 2021-03-24 |
| SG11202011378WA (en) | 2020-12-30 |
| US11542244B2 (en) | 2023-01-03 |
| WO2019222565A1 (en) | 2019-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103502203B (zh) | 制备l-鸟氨酸苯基乙酸盐的方法 | |
| EP2966072A2 (en) | Crystalline forms of nilotinib hydrobromide, succinate, glutamate, acetate, l-malate and maleate | |
| BRPI0922774B1 (pt) | Composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos | |
| WO2009056029A1 (en) | Purification method of pemetrexed salts,sodium salts and disodium salts | |
| CN104418841B (zh) | 一种光学纯雷贝拉唑及其钠盐的制备方法 | |
| JP5654462B2 (ja) | 貧溶媒添加法による２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法 | |
| JP6250629B2 (ja) | 高純度のシクロペプチド系物質の結晶およびその製造方法と使用 | |
| JP5519201B2 (ja) | ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法 | |
| PT2448945E (pt) | Formas cristalinas de sais de prasugrel | |
| CN105992761A (zh) | 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法 | |
| BR112020023559A2 (pt) | método para preparar um enantiômero de tipifarnib desejado e método para transformar uma amina enantiomericamente enriquecida | |
| CN105085486A (zh) | 一种右旋雷贝拉唑钠的精制方法 | |
| TWI705065B (zh) | 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途 | |
| JP7751124B2 (ja) | ７－アザスピロ［４，５］デカン－６，１０－ジオン化合物の結晶形及びその調製方法 | |
| DK2909169T3 (en) | CRYSTALLINIC PHASE OF (3S, 3S ') 4,4'-DISULPHANDYLBIS (3-AMINOBUTANE 1-SULPHONIC ACID) WITH L-LYSINE | |
| EA042764B1 (ru) | Способы получения (r)-(+)-типифарниба | |
| CN112204043B (zh) | 奈立膦酸钠的多晶型物及其制备工艺 | |
| JP4402361B2 (ja) | 塩酸エピナスチンの結晶多形 | |
| CN101353343A (zh) | 高纯度盐酸诺拉曲塞二水合物的制备方法 | |
| CN103497145A (zh) | 一种光学纯多奈哌齐的制备工艺 | |
| KR101129575B1 (ko) | 반수화물 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법 | |
| CN103113348A (zh) | 枸地氯雷他定的假多晶型及其制备方法 | |
| KR20110008559A (ko) | 무수결정형 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법 | |
| WO2018054359A1 (zh) | 一种喹唑啉衍生物的盐、其制备方法及应用 | |
| BR112019008420B1 (pt) | Processo para a preparação de 1-(4-clorofenil)pirazol-3-ol cristalino |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: KURA ONCOLOGY, INC. (US) |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |